169 related articles for article (PubMed ID: 33092037)
1. Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy.
Gawęda W; Pruszyński M; Cędrowska E; Rodak M; Majkowska-Pilip A; Gaweł D; Bruchertseifer F; Morgenstern A; Bilewicz A
Nanomaterials (Basel); 2020 Oct; 10(10):. PubMed ID: 33092037
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with
Cędrowska E; Pruszyński M; Gawęda W; Żuk M; Krysiński P; Bruchertseifer F; Morgenstern A; Karageorgou MA; Bouziotis P; Bilewicz A
Molecules; 2020 Feb; 25(5):. PubMed ID: 32106568
[TBL] [Abstract][Full Text] [Related]
3. Au@
Gharibkandi NA; Wawrowicz K; Majkowska-Pilip A; Żelechowska-Matysiak K; Wierzbicki M; Bilewicz A
EJNMMI Radiopharm Chem; 2023 Oct; 8(1):26. PubMed ID: 37821747
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab-Modified Gold Nanoparticles Labeled with
Dziawer Ł; Majkowska-Pilip A; Gaweł D; Godlewska M; Pruszyński M; Jastrzębski J; Wąs B; Bilewicz A
Nanomaterials (Basel); 2019 Apr; 9(4):. PubMed ID: 31003512
[TBL] [Abstract][Full Text] [Related]
5. Improvement of the Effectiveness of HER2+ Cancer Therapy by Use of Doxorubicin and Trastuzumab Modified Radioactive Gold Nanoparticles.
Żelechowska-Matysiak K; Salvanou EA; Bouziotis P; Budlewski T; Bilewicz A; Majkowska-Pilip A
Mol Pharm; 2023 Sep; 20(9):4676-4686. PubMed ID: 37607353
[TBL] [Abstract][Full Text] [Related]
6. Polypyrrole-Barium Ferrite Magnetic Cryogels for Water Purification.
Milakin KA; Taboubi O; Acharya U; Lhotka M; Pokorný V; Konefał M; Kočková O; Hromádková J; Hodan J; Bober P
Gels; 2023 Jan; 9(2):. PubMed ID: 36826262
[TBL] [Abstract][Full Text] [Related]
7. Multimodal Radiobioconjugates of Magnetic Nanoparticles Labeled with
Ünak P; Yasakçı V; Tutun E; Karatay KB; Walczak R; Wawrowicz K; Żelechowska-Matysiak K; Majkowska-Pilip A; Bilewicz A
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986710
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional Nanoparticles Based on Iron Oxide and Gold-198 Designed for Magnetic Hyperthermia and Radionuclide Therapy as a Potential Tool for Combined HER2-Positive Cancer Treatment.
Żuk M; Podgórski R; Ruszczyńska A; Ciach T; Majkowska-Pilip A; Bilewicz A; Krysiński P
Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015306
[TBL] [Abstract][Full Text] [Related]
9. Hybrid Radiobioconjugated Superparamagnetic Iron Oxide-Based Nanoparticles for Multimodal Cancer Therapy.
Żuk M; Gawęda W; Majkowska-Pilip A; Osial M; Wolski M; Bilewicz A; Krysiński P
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834258
[TBL] [Abstract][Full Text] [Related]
10. Preparation of
Westrøm S; Generalov R; Bønsdorff TB; Larsen RH
Nucl Med Biol; 2017 Aug; 51():1-9. PubMed ID: 28486098
[TBL] [Abstract][Full Text] [Related]
11. Nanozeolite bioconjugates labeled with
Piotrowska A; Męczyńska-Wielgosz S; Majkowska-Pilip A; Koźmiński P; Wójciuk G; Cędrowska E; Bruchertseifer F; Morgenstern A; Kruszewski M; Bilewicz A
Nucl Med Biol; 2017 Apr; 47():10-18. PubMed ID: 28043005
[TBL] [Abstract][Full Text] [Related]
12. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
Costantini DL; Chan C; Cai Z; Vallis KA; Reilly RM
J Nucl Med; 2007 Aug; 48(8):1357-68. PubMed ID: 17631548
[TBL] [Abstract][Full Text] [Related]
13. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin- and Trastuzumab-Modified Gold Nanoparticles as Potential Multimodal Agents for Targeted Therapy of HER2+ Cancers.
Żelechowska-Matysiak K; Wawrowicz K; Wierzbicki M; Budlewski T; Bilewicz A; Majkowska-Pilip A
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985421
[TBL] [Abstract][Full Text] [Related]
15. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F
Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab.
Yousefpour P; Atyabi F; Vasheghani-Farahani E; Movahedi AA; Dinarvand R
Int J Nanomedicine; 2011; 6():1977-90. PubMed ID: 21976974
[TBL] [Abstract][Full Text] [Related]
17. Biocompatibility and cytotoxicity in vitro of surface-functionalized drug-loaded spinel ferrite nanoparticles.
Mushtaq S; Shahzad K; Saeed T; Ul-Hamid A; Abbasi BH; Ahmad N; Khalid W; Atif M; Ali Z; Abbasi R
Beilstein J Nanotechnol; 2021; 12():1339-1364. PubMed ID: 34934608
[TBL] [Abstract][Full Text] [Related]
18. Targeted actinium-225 in vivo generators for therapy of ovarian cancer.
Borchardt PE; Yuan RR; Miederer M; McDevitt MR; Scheinberg DA
Cancer Res; 2003 Aug; 63(16):5084-90. PubMed ID: 12941838
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of an Anti-HER2 Nanobody Labeled with
Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
[TBL] [Abstract][Full Text] [Related]
20. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
Chen KT; Lee TW; Lo JM
Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
